Everest Medicines Limited (1952.HK)
Develops medicines and vaccines for kidney disease, infections, and immune disorders in Asia.
25.02+0.01%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-59.7%
The outlook
Everest Medicines trades near its 52-week low, well below both its 50- and 200-day moving averages, signaling weakness in recent price action. Analysts lean bullish with a "buy" consensus, and their average price target sits roughly 69% above the current level, though the stock's overall momentum remains subdued.
What’s behind the score
Analyst consensusBuy — 2.0 avg of 6 analysts
Price trendBelow its 50- & 200-day averages
52-week range4% of the way from its 52-week low to high
Price targetAvg target +69% vs current price
Analyst price target
~12-month · 6 analysts42.21average target+68.7% vs now
Now 25.02
Low 25.60High 69.09
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$8.79B
52-wk high
75.15
52-wk low
22.70
50-day avg
27.56
200-day avg
37.66
Trailing P/E
—